DelveInsight’s, “Cough in Idiopathic Pulmonary Fibrosis (IPF) Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cough in Idiopathic Pulmonary Fibrosis (IPF) pipeline landscape. It covers the Cough in Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cough in Idiopathic Pulmonary Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Cough in Idiopathic Pulmonary Fibrosis Pipeline Outlook Report
Key Takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report
- In August 2025, Boehringer Ingelheim announced a study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF. Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part.
- DelveInsight’s Cough in Idiopathic Pulmonary Fibrosis pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Cough in Idiopathic Pulmonary Fibrosis treatment.
- The leading Cough in Idiopathic Pulmonary Fibrosis Companies such as Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma and others.
- Promising Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapies such as Orvepitant Maleate, Gefapixant, BI 1839100, PA101, ME-015 (Suplatast Tosilate) and others.
Learn how leading Cough in Idiopathic Pulmonary Fibrosis Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Cough in Idiopathic Pulmonary Fibrosis Clinical Trials Assessment
Cough in Idiopathic Pulmonary Fibrosis Emerging Drugs Profile
- Haduvio (nalbuphine ER): Trevi Therapeutics
Haduvio (nalbuphine ER) has a novel approach to chronic cough by working on two important receptors that are critical mediators of cough, in both the central and peripheral nerves. Haduvio has a dual mechanism of action, acting as both an agonist (activator) to the kappa opioid receptor and as an antagonist (blocker) to the body’s mu opioid receptor. By targeting these receptors along the complete cough pathway, it has the potential to work regardless of whether the initial cough trigger originates in the lung or in the central nervous system. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF).
The Cough in Idiopathic Pulmonary Fibrosis Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Cough in Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cough in Idiopathic Pulmonary Fibrosis Treatment.
- Cough in Idiopathic Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Cough in Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cough in Idiopathic Pulmonary Fibrosis market.
From early-stage research to late-phase Cough in Idiopathic Pulmonary Fibrosis Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Cough in Idiopathic Pulmonary Fibrosis Treatment Drugs
Cough in Idiopathic Pulmonary Fibrosis Companies
Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma and others.
Cough in Idiopathic Pulmonary Fibrosis (IPF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Cough in Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Stay updated with the latest Cough in Idiopathic Pulmonary Fibrosis Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Cough in Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspectives
Scope of the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report
- Coverage– Global
- Cough in Idiopathic Pulmonary Fibrosis Companies- Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma and others.
- Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapies- Orvepitant Maleate, Gefapixant, BI 1839100, PA101, ME-015 (Suplatast Tosilate) and others.
- Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Cough in Idiopathic Pulmonary Fibrosis Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Cough in Idiopathic Pulmonary Fibrosis (IPF): Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Cough in Idiopathic Pulmonary Fibrosis (IPF)– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Mid Stage Products (Phase II)
- Haduvio (nalbuphine ER): Trevi Therapeutics
- Early Stage Products (Phase I)
- Drug name: Company name
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Inactive Products
- Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Companies
- Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Products
- Cough in Idiopathic Pulmonary Fibrosis (IPF)- Unmet Needs
- Cough in Idiopathic Pulmonary Fibrosis (IPF)- Market Drivers and Barriers
- Cough in Idiopathic Pulmonary Fibrosis (IPF)- Future Perspectives and Conclusion
- Cough in Idiopathic Pulmonary Fibrosis (IPF) Analyst Views
- Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight